Noveris Health Sciences, Inc. is a biotechnology company, which engages in the research, drug development, and clinical trials of psilocybin products. The company was founded by Parente Carman, Damon Michaels, and Robert Roscow on September 27, 2013 and is headquartered in Vancouver, Canada.
Sector:
Health Technology
Industry:
Pharmaceuticals Other
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Mydecine Innovations Group Inc - Ordinary Shares New market cap is $161,500.00.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Mydecine Innovations Group Inc - Ordinary Shares New 52 week high is $0.45 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Mydecine Innovations Group Inc - Ordinary Shares New 52 week low is $0.005 as of November 20, 2026.
Mydecine Innovations Group Inc - Ordinary Shares New stock price today is $0.1308.
Mydecine Innovations Group Inc - Ordinary Shares New stock price yesterday was $0.2182.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Mydecine Innovations Group Inc - Ordinary Shares New's P/E ratio is 0.1.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Mydecine Innovations Group Inc - Ordinary Shares New P/B ratio is -0.0148.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Mydecine Innovations Group Inc - Ordinary Shares New 50-day moving average is $0.1413.